Lataa...
A Prospective Open‐Label Observational Study of a Buffered Soluble 70 mg Alendronate Effervescent Tablet on Upper Gastrointestinal Safety and Medication Errors: The GastroPASS Study
Upper gastrointestinal (GI) side effects are a main reason for discontinuing bisphosphonate treatment, an important therapeutic option for osteoporosis patients. Consequently, the development of novel formulations with improved tolerability is warranted. In this multicenter prospective, observationa...
Tallennettuna:
| Julkaisussa: | JBMR Plus |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley & Sons, Inc.
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8260812/ https://ncbi.nlm.nih.gov/pubmed/34258506 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbm4.10510 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|